Findings highlight the Pfizer ... vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in children.

On Tuesday, the FDA approved Pfizer Inc’s (NYSE:PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract ...

NEW YORK, October 22, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE ... approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for ...

VSD also identified a signal for ischemic stroke for both mRNA vaccines, but the findings were not consistent. Previously, VSD identified a statistical signal for the Pfizer/BioNTech bivalent ...

Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...

Oct 22 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Pfizer's (PFE.N), opens new tab RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in ...

The Food and Drug Administration expanded its approval of Pfizer’s vaccine for a deadly respiratory virus to a new age group. The vaccine, called Abrysvo, has been approved for the prevention of ...

Although Merck’s vaccine, like Pfizer’s, is approved for use in people at least 18 years of age, Capvaxive is the only pneumococcal disease vaccine that was specifically made to protect adults ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Also Read: Bacterial Infections Vaccine Developer Vaxcyte’s Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher The 20 serotypes contained in Pfizer’s PREVNAR 20 are ...